Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Slides:



Advertisements
Similar presentations
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a.
Advertisements

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,
MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Do HSCs divide asymmetrically?
MBL: mostly benign lymphocytes, but…
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,
by Taizo Wada, Shepherd H. Schurman, G
Next-generation leukemia immunotherapy
by Venetia Bigley, Laura E. Spence, and Matthew Collin
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease by Marijke R. Canninga-van Dijk, Hanneke.
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study by Guillaume Cartron, Sophie de Guibert,
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood by Mohamed F. Elshal,
How I treat hairy cell leukemia
Lytic Replication of Epstein-Barr Virus in the Peripheral Blood: Analysis of Viral Gene Expression in B Lymphocytes During Infectious Mononucleosis and.
Rituximab-induced tumor cell agglutination
Tax fingerprint in adult T-cell leukemia
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia by John C. Byrd, Guido Marcucci,
How I treat elderly patients with myeloma
Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.
Mechanisms of HIV-associated lymphocyte apoptosis
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
by Romina Gamberale, Jorge R. Geffner, Julieta Sanjurjo, Paula X
Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.
Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma by Alexandra Albertsson-Lindblad, Arne Kolstad,
by Wolfram Springer, Alexander von Ruecker, and Roswitha Dickerhoff
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,
by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C
Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate by E.L.
Chronic neutropenia mediated by Fas ligand
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
Granulocyte colony-stimulating factor receptor mutations in a patient with acute lymphoblastic leukemia secondary to severe congenital neutropenia by Manuela.
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis by Albert Gutierrez,
Anergy: the CLL cell limbo
Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.
by Geling Li, Emily Waite, and Julie Wolfson
Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.
by Wendy Lim, Sara K. Vesely, and James N. George
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Anti-CD20-IL-21 fusokine: the tail wags the dog
Rituximab immunotherapy: it’s getting personal
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Distributions of CD4, Th1, and Th2 in adults (n = 16; A) and children (n = 50; B). Distributions of CD4, Th1, and Th2 in adults (n = 16; A) and children.
Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)‏ by Laura Moreno, Aintzane.
Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.
by Wolfgang Warsch, Christoph Walz, and Veronika Sexl
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed.
Cold agglutinin disease
Presentation transcript:

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)‏ by U. Winkler, M. Jensen, O. Manzke, H. Schulz, V. Diehl, and A. Engert Blood Volume 94(7):2217-2224 October 1, 1999 ©1999 by American Society of Hematology

U. Winkler et al. Blood 1999;94:2217-2224 ©1999 by American Society of Hematology

U. Winkler et al. Blood 1999;94:2217-2224 ©1999 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.